

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspro.gov

	FILING DAT	FIRST NAMED	INVENTOR ATTORNEY DOCKET NO.	CONFIRMATION NO.	
APPLICATION NO. 10/007,177	Election no.		raig Dyar 5962-01-CA	5683	
,	7590 02/	8/2004	EXAM	EXAMINER YOUNG, MICAH PAUL	
28880 WARNER-	LAMBERT CO		YOUNG, MI		
2800 PLYM(OUTH RD		ART UNIT	PAPER NUMBER	
ANN ARBO	R, MI 48105		1615		

DATE MAILED: 02/18/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		10/007,177	DYAR ET AL.			
		Examiner	Art Unit			
		Micah-Paul Young	1615			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)⊠ R	1) Responsive to communication(s) filed on 21 November 2003.					
•		s action is non-final.				
,—						
Disposition	of Claims					
4a 5)☐ C 6)☐ C 7)☐ C	4) ☐ Claim(s) 17-21 and 23 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected.					
Application	Papers					
 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. 						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some color None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date						
3) 🔲 Informat	f Draftsperson's Patent Drawing Review (PTO-948) ion Disclosure Statement(s) (PTO-1449 or PTO/SB/08 o(s)/Mail Date		ratent Application (PTO-152)			

Application/Control Number: 10/007,177

Art Unit: 1615

DETAILED ACTION

Acknowledgment of Papers Received: Amendment/Response filed 11/23/03.

Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 2. Claims 17-21 are rejected under 35 U.S.C. 102(b) as being anticipated by Bar-Shalom et al (USPN 5,618,560 hereafter referred to as '560). The claims are drawn to a method of making a pharmaceutical dosage form comprising co-extruding the dosage form along with a coating composition. The coating being impervious to water or bodily fluids. The dosage forms are then cut and cooled.
- 3. '560 discloses a method for making pharmaceutical dosage forms with coatings (abstract). The coating can be impervious to water or bodily fluids, and can be co-extruded with an active agent core (col. 8, lin. 5 19, lin 59 63; col. 11, lin. 49 col. 12, lin. 57). The dosage forms are extruded in cylindrical forming a molten state with temperatures between 60 and 80 degrees Celsius (examples 3). The dosage forms are allowed to cool, and then are cut into segments (example 5). These disclosures along with other render the method of manufacture anticipated.

Page 3

Application/Control Number: 10/007,177

Art Unit: 1615

Claim Rejections - 35 USC § 103

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 5. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 6. Claim 23 is rejected under 35 U.S.C. 103(a) as being unpatentable over Bar-Shalom et al (USPN 5,618,560 hereafter referred to as '560). The claim is drawn to a method of making a dosage form where the form is co-extruded and sliced into segments with a laser.
- 7. As discussed above '560 discloses a process for making pharmaceutical dosage form comprising co-extruding an impervious coating and a core, cooling the extrudate and slicing it into segments. However it is the position of the examiner that the laser slicing does not provide any structural difference or distinctive property to the resultant dosage forms. The examiner invites applicant to provide evidence that the laser slicing does in fact distinguish extruded pellets one from the other. The Office does not have the facilities for examining and comparing applicant's product with the product of the prior art in order to establish that the product of the prior art does not possess the same material structural and functional characteristics of the claimed product. In the absence of evidence to the contrary, the burden is upon the applicant to prove that the claimed products are functionally different than those taught by the prior art and to establish patentable differences. See Ex parte Phillips, 28 U.S.P.Q.2d 1302, 1303 (PTO Bd. Pat.

Application/Control Number: 10/007,177

Art Unit: 1615

App. & Int. 1993), Ex parte Gray, 10 USPQ2d 1922, 1923 (PTO Bd. Pat. App. & Int.) and In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977).

8. With these things in mind, it would have been obvious to one of ordinary skill in the art would be motivated to slice extruded segments in the way best fit for the purposes of the invention. The skilled artisan would have been motivated to follow the suggestions and teachings of '560 with an expected result of a method for making and slicing dosage forms.

Response to Arguments

9. Applicant's arguments with respect to claims 17-21 and 23 have been considered but are most in view of the new ground(s) of rejection.

Conclusion

10. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

Application/Control Number: 10/007,177 Page 5

Art Unit: 1615

however, will the statutory period for reply expire later than SIX MONTHS from the date of this

final action.

Correspondence

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Micah-Paul Young whose telephone number is 571-272-0608.

The examiner can normally be reached on M-F 7:00-4:30 every other Monday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Thurman K Page can be reached on 571-272-0602. The fax phone number for the

organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Micah-Paul Young

Examiner

Art Unit 1615

MP Young

Gollamudi S. Kishore, PhD

Primary Examiner

Group 1500